Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Purchased by Northern Trust Corp

Northern Trust Corp raised its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 19.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 694,142 shares of the company's stock after purchasing an additional 112,534 shares during the period. Northern Trust Corp owned 0.88% of Viridian Therapeutics worth $13,307,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in VRDN. FMR LLC increased its position in shares of Viridian Therapeutics by 6.2% during the fourth quarter. FMR LLC now owns 11,881,912 shares of the company's stock worth $227,776,000 after acquiring an additional 698,434 shares during the period. Vanguard Group Inc. increased its holdings in Viridian Therapeutics by 4.0% during the fourth quarter. Vanguard Group Inc. now owns 4,595,049 shares of the company's stock valued at $88,087,000 after buying an additional 174,952 shares during the period. Alliancebernstein L.P. increased its holdings in Viridian Therapeutics by 3.8% during the fourth quarter. Alliancebernstein L.P. now owns 2,286,994 shares of the company's stock valued at $43,842,000 after buying an additional 84,255 shares during the period. Adage Capital Partners GP L.L.C. grew its holdings in Viridian Therapeutics by 38.6% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,670,000 shares of the company's stock worth $32,014,000 after purchasing an additional 465,000 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Viridian Therapeutics by 11.1% during the fourth quarter. Geode Capital Management LLC now owns 1,658,980 shares of the company's stock worth $31,809,000 after buying an additional 165,669 shares during the period.

Analyst Ratings Changes

A number of research firms have weighed in on VRDN. JMP Securities cut their price objective on shares of Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating for the company in a report on Wednesday, May 7th. The Goldman Sachs Group dropped their price objective on shares of Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Royal Bank of Canada decreased their target price on shares of Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Needham & Company LLC reaffirmed a "buy" rating and set a $36.00 target price on shares of Viridian Therapeutics in a research note on Tuesday. Finally, HC Wainwright reissued a "buy" rating and issued a $34.00 price objective on shares of Viridian Therapeutics in a research report on Wednesday, April 23rd. One analyst has rated the stock with a hold rating and ten have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $36.70.

Viridian Therapeutics Stock Down 1.5%

Shares of Viridian Therapeutics stock traded down $0.21 on Wednesday, hitting $13.61. The company had a trading volume of 58,609 shares, compared to its average volume of 1,189,164. Viridian Therapeutics, Inc. has a twelve month low of $9.90 and a twelve month high of $27.20. The stock has a 50-day moving average of $13.29 and a 200-day moving average of $17.01. The firm has a market capitalization of $1.11 billion, a P/E ratio of -3.14 and a beta of 0.57. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.95) by $0.08. The business had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.16 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The business's revenue was up .0% on a year-over-year basis. Research analysts predict that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.